Very interesting data from the latest study and successful share issue. Significant events during the first quarter of 2025In January, Nanexa announced that the company had decided to carry out a dire ...

Tirzapetide dose escalation schedules were slower in the real-world than clinical settings among individuals with obesity without T2D.